Summit Therapeutics Inc. (SMMT)
$17.59+2.45%Close
BUYRECOVERY · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV39.8%–326.7%
- Market cap
- $13.7B
- Beta
- -1.24
- P/E (TTM)
- -15.46
- IV-%ile
- 46
- IV ATM
- 85.0%
- Short % float
- 38.33%
- Days to cover
- 4.8
- SI change
- +0.2%
- 1W
- +4.95%
- 1M
- +3.47%
- vs SPY 1W
- +3.79%
- vs SPY 1M
- +0.48%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on SMMT?
- LOPJLB’s latest quantitative signal on Summit Therapeutics Inc. (SMMT) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is SMMT in?
- Summit Therapeutics Inc. (SMMT) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Summit Therapeutics Inc. (SMMT) do?
- Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an …